NEXIUM Formulary Database

The NEXIUM formulary database* is a simple-to-use tool that allows you to determine NEXIUM coverage for the health plans specific to your area. Simply select your state and up to two health plans. Your results will show available coverage and any restrictions that may apply.

*Formulary information is provided by Fingertip FormularyTM

Select Your State

After selecting a state, a list of health plans in your area will appear.

Select Your Health Plan

You may choose up to 2 healthcare plans. Your result will appear to the right.

Results

Print your results or change your selections.


This information is provided for general informational purposes only and is current as of 1/6/2009. Individual plans may vary and all information is subject to change. For the most current formulary information, contact your patient's drug benefit provider.

Important Safety Information About NEXIUM

Treatment of Gastroesophageal Reflux Disease (GERD)
Healing of Erosive Esophagitis (EE): NEXIUM is indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed EE.

Maintenance of Healing of EE: NEXIUM is indicated to maintain symptom resolution and healing of EE. Controlled studies did not extend beyond 6 months.

Symptomatic GERD: NEXIUM is indicated for the treatment of heartburn and other symptoms associated with GERD.

Pediatric Use: NEXIUM is indicated for the short-term treatment (up to 8 weeks) of GERD (symptomatic GERD and healing of EE) in patients 1 to 17 years of age. Pediatric use is supported by extrapolation of results from studies that supported the approval for NEXIUM for adults and safety and pharmacokinetic studies performed in pediatric and adolescent patients. Safety and effectiveness for the treatment of symptomatic GERD in patients less than 1 year of age have not been established. Safety and effectiveness for other pediatric uses have not been established.

Important Safety Information

  • NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles
  • In adult patients, the most frequently reported adverse events (AEs) with NEXIUM include headache, diarrhea, and abdominal pain
  • In pediatric patients 1 to 17 years of age, the most frequently reported AEs with NEXIUM include headache, diarrhea, abdominal pain, nausea, and somnolence
  • Symptomatic response to therapy does not preclude the presence of gastric malignancy.
  • Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which NEXIUM is an enantiomer
  • As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time. Like other PPIs, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts, and digoxin)
  • Concomitant use of atazanavir and PPIs is not recommended because the plasma concentrations of atazanavir are expected to substantially decrease and thereby reduce its therapeutic effect.
  • NEXIUM should be used only for the conditions, dosages, and durations specified in the Prescribing Information. Dosing for adults and pediatrics is provided in the Prescribing Information
  • Please click here to see the full Prescribing Information pdf (PDF – 303 KB) for NEXIUM